Company Overview and News
KUALA LUMPUR, Sept 21 — Shares on Bursa Malaysia remained in positive territory at mid-morning, supported by persistent buying in selected heavyweights and buoyed by optimism over a possible lenient outcome on the US-China trade negotiations.
PBLOF 0026 1295 BSMAF 1818
KUALA LUMPUR, Sept 21 — Shares on Bursa Malaysia were on a positive momentum in early trading today, in line with overnight gains in most Asian markets, buoyed by optimism over a possible lenient outcome on the US-China trade negotiations.
PBLOF 1295 BSMAF 1818
KUALA LUMPUR, Sept 20 — Bursa Malaysia ended higher for the second consecutive day today on continued buying interest in selected heavyweights and finance counters, and in line with most regional bourses, dealers said.
PBLOF 7036 1295 BSMAF HIPEF 1818 5199
KUALA LUMPUR, Sept 20 ― Bursa Malaysia ended the morning session on positive note, with the key composite index rising 0.23 per cent and in line with positive sentiment among regional peers, analysts said.
PBLOF 1295 BSMAF HIPEF 1818 5199
KUALA LUMPUR, Sept 20 ― Share prices on Bursa Malaysia extended gains from yesterday to open higher today on continued buying in selected heavyweights and despite the mixed sentiment on regional markets, dealers said.
PBLOF 1295 BSMAF 5256 1818
MOST Malaysian banks saw a weakening of asset quality in the second quarter on a sequential basis, but Affin Bank Bhd’s was the most pronounced as it had the biggest impact on earnings, no thanks to two problematic accounts.
1155 1023 PBLOF MLYBY MLYNF 5819 1295 CIMDF
KUALA LUMPUR (Sept 19): The FBM KLCI rose 0.53% at midday break today, tracking the broad-based uptrend at regional markets, while staying above the crucial 1,800-point level.
HLFBF 7052 PBLOF 7060 8621 1082 7113 TPGVF BATS 4162 1163 1295 6033 5199 TGLVY 4588 PNADF 3026 0026 5819 HIPEF PNAGF
Banking sector Maintain neutral: The negative surprise in banks’ financial results for second quarter of 2018 (2Q18) was the 1.5% year-on-year (y-o-y) drop in operating revenues. At the top line, net interest incomes slid by 3.1% y-o-y in 2Q18 under the pressure of margin contraction arising from stiff competition for deposits. Also, non-interest incomes fell by 9.2% y-o-y in 2Q18, owing to lower investment incomes and weak expansion in fee incomes.
1015 PBLOF AMMHF 1295
KUALA LUMPUR (Sept 19): The FBM KLCI rose 0.53% at mid-morning today and climbed above the 1,800-point level, tracking gains at the regional markets.
HLFBF PBLOF 1082 7113 5681 TPGVF 1295 5168 3794 6033 TGLVY 5238 4588 PNADF 1201 0026 5819 PNAGF HRGHY
KUALA LUMPUR, Sept 19 — Share prices on Bursa Malaysia rebounded from yesterday's losses to open higher today, inline with most regional bourses, on renewed buying demand as equities were attractive at current prices, dealers said.
5238 PBLOF 7036 1295 BSMAF 1818
KUALA LUMPUR, Sept 18 — Bursa Malaysia ended lower on continued selling of heavyweights in line with most regional markets as investors remained cautious amid renewed concerns over the US-China trade dispute, dealers said.
PBLOF 0026 1295 BSMAF 7123 1818
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET